Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 17 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

Mortality trends and high-risk subgroups in hematologic malignancy-associated pulmonary embolism: a population-based analysis with complementary clinical data

  • Xi Quan1
  • Ping Zhang1
  • Nan Zhang1
  • Jing Wu2
  • Shifeng Lou1
  • Zhiming Luo1
  1. 1Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University
  2. 2Department of Hematology-Oncology, Chongqing University Cancer Hospital, Hematologic Oncology Intelligent Diagnosis and Treatment Engineering Research Center of Chongqing Education Commission of China
Open at sourcePDFDOICite

Abstract

Objective: Pulmonary embolism (PE) is an important supportive care concern in patients with hematologic malignancies, particularly older adults with coexisting thrombotic, bleeding, comorbidity, and treatment-related risks. This study first characterized temporal and demographic patterns in U.S. population-level mortality records involving hematologic malignancies and PE, followed by a complementary single-center real-world analysis of 30-day all-cause mortality and potentially vulnerable age- and sex-defined subgroups.

Methods: Using CDC WONDER data, we analyzed U.S. mortality records from 1999 to 2023 and calculated age-adjusted mortality rates (AAMRs), annual percentage changes (APCs), and average annual percentage changes (AAPCs). We also analyzed a single-center retrospective cohort to describe 30-day all-cause mortality according to age and sex.

Results: Population-level mortality from hematologic malignancies declined from 1999 to 2023 (AAPC, −1.75%; 95% CI, −1.81% to −1.69%), whereas mortality records involving hematologic malignancies and PE increased, with a faster rise after 2017 (APC, 3.02%; 95% CI, 0.51%–5.58%). Higher mortality rates were observed among males, individuals aged ≥75 years, non-Hispanic Black individuals, residents of the Western United States, and nonmetropolitan populations. In the complementary clinical cohort, 30-day mortality was 30.77% among patients aged ≥75 years and 14.63% among those aged <75 years (P = 0.223), and 16.95% among males and 16.67% among females (P = 1.000).

Conclusion: Although overall mortality among patients with hematologic malignancies decreased over the past two decades, mortality involving hematologic malignancies and PE remained an important supportive care concern with persistent demographic and geographic disparities. Complementary real-world observations showed a numerically higher 30-day all-cause mortality in older patients, although the difference was not statistically significant. These findings support careful clinical assessment of potentially vulnerable patients and individualized supportive care that considers thrombotic risk, bleeding risk, comorbidity burden, and underlying malignancy characteristics.

Related

  1. Bloodstream Infections in Patients with Malignancy: Microbiological Epidemiology, Antimicrobial Resistance, and Factors Associated with Mortality in a Nine-Year Single-Center Retrospective Cohort
    Cihan Yeşil, Cemile Arslan Yeşil, Ferhat Yılmaz +2
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Eosinophilic Esophagitis and Marked Leukocytosis in Alpha-Gal Syndrome: Infection, Allergy, or Hematologic Malignancy?
    Mohamed Alharami, Christina Kafkis, Omar Alwan +3
    CureusPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  3. Endpoint-specific mortality associated with malignancy among adults with sepsis or septic shock: a systematic review and meta-analysis
    Huei Chung, Hung-Chang Chou, Tsung-Yu Tsai +1
    Annals of MedicinePeer-reviewedCC BY 4.0Full textInfectious diseasePMC
  4. Clinical and microbiological characteristics of abscesses in patients with malignancy and factors associated with 90-day mortality
    Huseyin Gencer, Fahriye Tugba Kos, Mustafa Guven +4
    Frontiers in Cellular and Infection MicrobiologyPeer-reviewedCC BY 4.0Full textOncologyPMC
  5. Age, period, and cohort effects in the population-level incidence and mortality of cancer types associated with early onset increases in Australia
    Sithum Munasinghe, Kate McBride, Phuong Dung Nguyen +2
    BMC MedicinePeer-reviewedCC BY-NC-ND 4.0OncologyCrossref

Cite

BibTeXRIS
BibTeX
@article{quan2026mortality,
  title = {{Mortality trends and high-risk subgroups in hematologic malignancy-associated pulmonary embolism: a population-based analysis with complementary clinical data}},
  author = {Xi Quan and Ping Zhang and Nan Zhang and Jing Wu and Shifeng Lou and Zhiming Luo},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1989633},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1989633/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Mortality trends and high-risk subgroups in hematologic malignancy-associated pulmonary embolism: a population-based analysis with complementary clinical data
AU  - Xi Quan
AU  - Ping Zhang
AU  - Nan Zhang
AU  - Jing Wu
AU  - Shifeng Lou
AU  - Zhiming Luo
PY  - 2026
DA  - 2026/10/28
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1989633
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1989633/full
AB  - Objective: Pulmonary embolism (PE) is an important supportive care concern in patients with hematologic malignancies, particularly older adults with coexisting thrombotic, bleeding, comorbidity, and treatment-related risks. This study first characterized temporal and demographic patterns in U.S. population-level mortality records involving hematologic malignancies and PE, followed by a complementary single-center real-world analysis of 30-day all-cause mortality and potentially vulnerable age- and sex-defined subgroups.  Methods: Using CDC WONDER data, we analyzed U.S. mortality records from 1999 to 2023 and calculated age-adjusted mortality rates (AAMRs), annual percentage changes (APCs), and average annual percentage changes (AAPCs). We also analyzed a single-center retrospective cohort to describe 30-day all-cause mortality according to age and sex.  Results: Population-level mortality from hematologic malignancies declined from 1999 to 2023 (AAPC, −1.75%; 95% CI, −1.81% to −1.69%), whereas mortality records involving hematologic malignancies and PE increased, with a faster rise after 2017 (APC, 3.02%; 95% CI, 0.51%–5.58%). Higher mortality rates were observed among males, individuals aged ≥75 years, non-Hispanic Black individuals, residents of the Western United States, and nonmetropolitan populations. In the complementary clinical cohort, 30-day mortality was 30.77% among patients aged ≥75 years and 14.63% among those aged <75 years (P = 0.223), and 16.95% among males and 16.67% among females (P = 1.000).  Conclusion: Although overall mortality among patients with hematologic malignancies decreased over the past two decades, mortality involving hematologic malignancies and PE remained an important supportive care concern with persistent demographic and geographic disparities. Complementary real-world observations showed a numerically higher 30-day all-cause mortality in older patients, although the difference was not statistically significant. These findings support careful clinical assessment of potentially vulnerable patients and individualized supportive care that considers thrombotic risk, bleeding risk, comorbidity burden, and underlying malignancy characteristics.
SN  - 2234-943X
ER  -